Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Raw Materials (2019 - 2025)

Historic Raw Materials for Karyopharm Therapeutics (KPTI) over the last 7 years, with Q4 2025 value amounting to $628000.0.

  • Karyopharm Therapeutics' Raw Materials fell 1277.78% to $628000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $628000.0, marking a year-over-year decrease of 1277.78%. This contributed to the annual value of $628000.0 for FY2025, which is 1277.78% down from last year.
  • Karyopharm Therapeutics' Raw Materials amounted to $628000.0 in Q4 2025, which was down 1277.78% from $630000.0 recorded in Q3 2025.
  • In the past 5 years, Karyopharm Therapeutics' Raw Materials ranged from a high of $2.6 million in Q1 2022 and a low of $261000.0 during Q2 2022
  • Moreover, its 5-year median value for Raw Materials was $720000.0 (2024), whereas its average is $1.0 million.
  • Its Raw Materials has fluctuated over the past 5 years, first plummeted by 8569.86% in 2022, then surged by 33065.13% in 2023.
  • Over the past 5 years, Karyopharm Therapeutics' Raw Materials (Quarter) stood at $1.8 million in 2021, then decreased by 23.76% to $1.4 million in 2022, then tumbled by 59.64% to $553000.0 in 2023, then surged by 30.2% to $720000.0 in 2024, then dropped by 12.78% to $628000.0 in 2025.
  • Its Raw Materials was $628000.0 in Q4 2025, compared to $630000.0 in Q3 2025 and $477000.0 in Q2 2025.